1-8 of 8
Evelyn Degenhard
Close
Sort by
Journal Articles

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Andreas Viardot, Mariele Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2014) 124 (21): 4460.
https://doi.org/10.1182/blood.V124.21.4460.4460
Published: 2014
Journal Articles

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Andreas Viardot, Mariele Goebeler, Michael Pfreundschuh, Nicole Adrian, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2013) 122 (21): 1811.
https://doi.org/10.1182/blood.V122.21.1811.1811
Published: 2013
Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Brief Report
Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Evelyn Degenhard, Marie-Elisabeth Goebeler, Matthias Klinger, Svenja A. Neumann, Heinz A. Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Markus Schaich, Rudolf Köhne-Volland, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Patrick A. Baeuerle, Dirk Nagorsen, Margit Schmidt, Hermann Einsele, Gert Riethmüller, Michael Kneba, Dieter Hoelzer, Peter Kufer, Ralf C. Bargou
Journal: Blood
Blood (2012) 120 (26): 5185–5187.
https://doi.org/10.1182/blood-2012-07-441030
Published: 2012
Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Clinical Trials & Observations
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer
Journal: Blood
Blood (2012) 119 (26): 6226–6233.
https://doi.org/10.1182/blood-2012-01-400515
Published: 2012
Includes: Supplemental data
Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Andreas Viardot, MD, Mariele Goebeler, MD, Richard Noppeney, MD, Stefan W. Krause, MD, Stefan Kallert, MD, Barbara Ferstl, MD, Andreas Mackensen, Kathrin Rupertus, MD, Martin Soekler, MD, Lothar Kanz, MD, Stefan Knop, MD, Max S. Topp, MD, Jurgen Scheele, MD, PhD, Dirk Nagorsen, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Margit Schmidt, PhD, Peter Kufer, MD, Martin Libicher, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2011) 118 (21): 1637.
https://doi.org/10.1182/blood.V118.21.1637.1637
Published: 2011
Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Max S Topp, Gerhard Zugmaier, MD, Nicola Goekbuget, MD, Svenja Neumann, MD, Heinz-August Horst, MD, Thorsten Raff, MD, Monika Brueggemann, MD, Michael Kneba, MD, Andreas Viardot, MD, Mathias Schmid, MD, Markus Schaich, MD, Matthias Stelljes, MD, Mariele Goebeler, MD, Heike Pfeiffer, MD, Oliver Ottmann, MD, Thomas Burmeister, MD, Evelyn Degenhard, Margit Schmidt, PhD, Jürgen Scheele, MD, PhD, Hermann Einsele, MD, Peter Kufer, MD, Matthias Klinger, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 174.
https://doi.org/10.1182/blood.V116.21.174.174
Published: 2010
Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Max S Topp, Gerhard Zugmaier, Nicola Goekbuget, Peter Kufer, Mariele Goebeler, Matthias Klinger, Evelyn Degenhard, Patrick A Baeuerle, Margit Schmidt, Dirk Nagorsen, Svenja Neumann, Heinz A Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Mathias Schmid, Oliver G. Ottmann, Thomas Burmeister, Hermann Einsele, Gert Riethmueller, Dieter Hoelzer, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 840.
https://doi.org/10.1182/blood.V114.22.840.840
Published: 2009
Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD
Journal: Blood
Blood (2008) 112 (11): 1926.
https://doi.org/10.1182/blood.V112.11.1926.1926
Published: 2008